Close Menu

NEW YORK (GenomeWeb) – QED Therapeutics said today that it has partnered with Foundation Medicine to develop a companion diagnostic for its drug candidate infigratinib in patients with cholangiocarcinoma (bile duct cancer).

Infigratinib is an FGFR1-3-selective tyrosine kinase inhibitor, and the CDx will include the detection of activating FGFR2 fusions. It is expected to be incorporated into FoundationOne CDx, Foundation Medicine's FDA-approved comprehensive genomic profiling assay for all solid tumors, which includes several companion diagnostics.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.